Your daily guide to ASCO 2023 research presentations by ECOG-ACRIN and PrECOG
Researchers with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and PrECOG, LLC, will present a wide range of abstracts at the 2023 annual meeting of the American Society of Clinical Oncology (ASCO), occurring in Chicago and online during the first weekend in June. Evaluations of innovative approaches to cancer treatment and survivorship are among the data.
Below, please find the essential information for the 17 presentations, along with a link to the related abstracts. For registered virtual attendees, ASCO plans to make most sessions available on demand shortly after their live presentation.
Saturday, June 3
- Developmental Therapeutics (NCI-MATCH) — Phase II study of crizotinib in patients with MET amplification and MET exon 14 deletion: Results from NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocols C1 and C2
Niamh Coleman, PhD, MBBCh, MRCP (MD Anderson Cancer Center)
8:00-11:00 AM CDT | Poster Board 306 | Hall A
Abstract 3108 - Genitourinary Cancer (Kidney) — Core biopsy accuracy and safety of biopsy and preoperative immunotherapy in predicting histological subtype and nuclear grade in ECOG-ACRIN EA8143 perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy
Naomi B. Haas, MD (University of Pennsylvania)
8:00-11:00 AM CDT | Poster Board 33 | Hall A
Abstract 4541 - Genitourinary Cancer (Prostate) — Patient-reported quality of life (QOL) and survival outcomes: analysis of ECOG-ACRIN E3805 chemohormonal androgen ablation randomized trial (CHAARTED) in prostate cancer
Daniel Sentana-Lledo, MD (Beth Israel Deaconess Medical Center)
8:00-11:00 AM CDT | Poster Board 108 | Hall A
Poster Discussion: 1:15 PM CDT | Room E450
Abstract 5014 - Genitourinary Cancer (Prostate) — Landscape and impact of germline pathogenic variants in metastatic hormone sensitive prostate cancer: ancillary study of E3805 CHAARTED
Anis Hamid, MBBS (University of Melbourne)
8:00-11:00 AM CDT | Poster Board 176 | Hall A
Abstract 5082 - Genitourinary Cancer (Prostate) — Trial in Progress — Phase III study of local or systemic therapy intensification directed by PET in prostate cancer patients with post-prostatectomy biochemical recurrence (INDICATE): ECOG-ACRIN EA8191
Neha Vapiwala, MD (University of Pennsylvania)
8:00-11:00 AM CDT | Poster Board 202a | Hall A
Abstract TPS5118 - Gianni Bonadonna Breast Cancer Award — Angela DeMichele, MD, MSCE
Presented during the Opening Session, 9:30 AM |Hall B1
Lecture available only on demand
Dr. DeMichele co-chairs ECOG-ACRIN’s Breast Cancer Committee and is a lead investigator for the PALLAS trial by PrECOG and other international collaborators - Breast Cancer — Updates on abstract 390216: adjuvant palbociclib for ER+ breast cancer (PALLAS Trial, ABCSG-42/AFT-05/PrE0109/BIG-14-13): a preplanned analysis of the stage IIA cohort
Angela DeMichele, MD, MSCE (University of Pennsylvania)
12:30-1:45 PM CDT (Dr. DeMichele’s presentation begins at 12:36) | Arie Crown Theatre
No abstract available
Part of the ASCO Plenary Series: Rapid Abstract Updates - Breast Cancer — BRACELET-1 (PrE0113): Inducing an inflammatory phenotype in metastatic HR+/HER2- breast cancer with the Oncolytic reovirus pelareorep in combination with paclitaxel and avelumab
Amy S. Clark, MD, MSCE (University of Pennsylvania)
1:15-2:45 PM CDT (Dr. Clark's presentation begins at 2:03) | Room S406
Oral Abstract 1012
Part of the Dr. Bernard Fisher Memorial Annual Clinical Science Symposium - Prevention, Risk Reduction, and Hereditary Cancer (Germline Genetic Testing) — Characterizing medical mistrust in a socio-demographically diverse sample of patients with cancer
Cindy Park, MD (Temple University)
1:15-4:15 PM CDT | Poster Board 184 | Hall A
Abstract 10551 - Prevention, Risk Reduction, and Hereditary Cancer (Germline Genetic Testing) — Modeling genetic testing attitudes in a socio-demographically diverse cohort of patients with cancer: The importance of race/ethnicity and medical mistrust
Michael J. Hall, MD, MSc (Fox Chase Cancer Center)
1:15-4:15 PM CDT | Poster Board 195 | Hall A
Abstract 10562
Sunday, June 4
- Breast Cancer — ECOG-ACRIN E2197: Comparison of HER2 gene expression by RT-PCR across all HER2 immunohistochemistry groups with recurrence analysis
Nhu Thuy Can, MD (Genomic Health); Sunil S. Badve, MD (Emory University)
8:00-11:00 AM CDT | Poster Board 345 | Hall B1
Poster Discussion: 4:30 PM CDT | Hall B1
Abstract 515 - Lung Cancer (Mesothelioma) — Trial in Progress — Durvalumab with chemotherapy as first line treatment in advanced pleural mesothelioma: a phase 3, randomized trial (DREAM3R or PrE0506)
Patrick M. Forde, MD (Johns Hopkins University)
8:00-11:00 AM CDT | Poster Board 226a | Hall A
Abstract TPS8599 - Lung Cancer — Trial in Progress — ECOG-ACRIN LUNG-MAP S1900E substudy: a phase II study of sotorasib in participants with previously treated stage IV or recurrent KRAS G12C mutant non-squamous non-small cell lung cancer
Sukhmani Kaur Padda, MD (Cedars-Sinai Medical Center)
8:00-11:00 AM CDT | Poster Board 129a | Hall A
Abstract TPS9143
Monday, June 5
- Gastrointestinal Cancer (Pancreatic NETs) — Novel use of alternate response criteria for early prediction of outcomes in pancreatic neuroendocrine tumors (NETs): Utilizing banked imaging data from the ECOG-ACRIN E2211 study
Namrata Vijayvergia, MD (Fox Chase Cancer Center)
8:00-11:00 AM CDT | Poster Board 454 | Hall A
Abstract 4133 - Care Delivery and Regulatory Policy — Smoking cessation support and knowledge among newly diagnosed individuals at community cancer centers (ECOG-ACRIN trial EAQ171CD)
Elyse R. Park, PhD, MPH (Massachusetts General Hospital)
1:15-4:15 PM CDT | Poster Board 116 | Hall A
Abstract 1522 - Head and Neck Cancer — Outcomes by time to adjuvant therapy in E3311, a phase II trial of transoral surgery followed by pathology-based adjuvant treatment in HPV-associated oropharynx cancer
Robert L. Ferris MD, PhD (Hillman Cancer Center)
1:15-4:15 PM CDT | Poster Board 28 | Hall A
Abstract 6036 - Symptoms and Survivorship — Impact of immune checkpoint inhibition on ovarian reserve in patients with melanoma enrolled in the ECOG-ACRIN E1609 adjuvant trial
Elizabeth I. Buchbinder, MD (Dana-Farber Cancer Institute)
1:15-4:15 PM CDT | Poster Board 381 | Hall A
Poster Discussion: 4:30 PM CDT | Room S404
Abstract 12013 - Prevention, Risk Reduction, and Hereditary Cancer — Incidence round screening performance among women with dense breasts undergoing abbreviated breast MRI and digital breast tomosynthesis (ECOG-ACRIN EA1141)
Christiane K. Kuhl, MD (Rheinisch-Westfälische Technische Hochschule Aachen)
3:00-6:00 PM CDT (Dr. Kuhl's presentation begins at 3:24) | Room S100a
Oral Abstract 10502
Publication Only
- Bioinformatics — A Lasso Cox score consisting of CTLA4+ regulatory T cells, monocytic myeloid derived suppressor cells, and CXCR3+ CD8+ T cells: association with adjuvant ipilimumab survival outcomes in patients with high-risk melanoma
Alyssa Obermayer (H. Lee Moffitt Cancer Center)
Abstract e21557